Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparison of Drug Eluting Balloon and Drug Eluting Stent (DEBfirst)

This study has been completed.
Information provided by (Responsible Party):
Chang-Hwan Yoon, Seoul National University Bundang Hospital Identifier:
First received: February 21, 2012
Last updated: June 11, 2015
Last verified: June 2015
The purpose of this study is to evaluate the safety and efficacy of Drug-Eluting Balloon first and then bare metal stent compared with drug-eluting stent for treatment of de novo lesions (DEB first).

Condition Intervention Phase
Coronary Artery Disease
Stable Angina
Unstable Angina
Device: Drug eluting balloon + Bare metal stent
Device: drug eluting stent (Zotarolimus-eluting stent)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparison of Drug-Eluting Balloon First and Then Bare Metal Stent With Drug-eluting Stent for Treatment of de Novo Lesions (DEB First): A Randomized Controlled Single Center Clinical Trial

Further study details as provided by Chang-Hwan Yoon, Seoul National University Bundang Hospital:

Primary Outcome Measures:
  • in-segment late loss [ Time Frame: 9 month ]
    angiographic in-segment late loss measure by QCA program

Secondary Outcome Measures:
  • stent thrombosis [ Time Frame: 9 month ]
    any stent thrombosis

  • angiographic and procedure success [ Time Frame: 9 month ]

    Angiographic success denotes that residual diameter stenosis is less than 10% without complication such as coronarhy dissection or thrombosis.

    Procedural success means that adequate DEB+BMS or DES delivery to the target lesion without geographic miss.

  • MACE [ Time Frame: 9 month ]
    death, MI and TVF

Enrollment: 180
Study Start Date: April 2011
Study Completion Date: February 2015
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DEB-BMS
Drug eluting balloon + Bare metal stent
Device: Drug eluting balloon + Bare metal stent
PCI using Sequent Please and then Coroflex Blue
Other Names:
  • Sequent Please (B.Braun, drug eluting balloon)
  • Coroflex Blue (B.Braun, bare metal stent)
Active Comparator: Drug eluting stent
conventional PCI with drug eluting stent drug eluting stent (Zotarolimus-eluting stent)
Device: drug eluting stent (Zotarolimus-eluting stent)
conventional PCI using Endeavor Integrity
Other Names:
  • Endeavor integrity
  • Zotarolimus-eluting stent

Detailed Description:

A recent trial to test premount bare metal stent on drug-eluting balloon failed to demonstrate non-inferiority and safety compared to drug-eluting stent alone for treatment of coronary artery stenosis.

We think that inappropriate drug delivery to diseased vessel due to stent strut might affect the efficacy of drug-eluting balloon. Therefore, we design a clinical study with a different protocol, that is, drug-eluting balloon first and then bare metal stent implantation in comparison to drug-eluting stent.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • De novo lesion
  • 2.5mm =< Reference diameter =< 4mm
  • Lesion length =< 28mm
  • Type A, B1/B2 lesion

Exclusion Criteria:

  • ST-segment elevation MI
  • Reference diameter < 2.5mm or > 4mm
  • Bifurcation lesion
  • Type C lesion
  • history of AMI or stroke within 1 year F. chronic renal disease (Cr > 2mg/dL)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01539603

Korea, Republic of
Seoul National Universtiy Bundang Hospital
Seongnam, Korea, Republic of, 463-707
Sponsors and Collaborators
Seoul National University Bundang Hospital
Principal Investigator: In-Ho Chae, MD Seoul National University Bundang Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Chang-Hwan Yoon, Assistant professor, Seoul National University Bundang Hospital Identifier: NCT01539603     History of Changes
Other Study ID Numbers: E-1104/061-001
Study First Received: February 21, 2012
Last Updated: June 11, 2015

Keywords provided by Chang-Hwan Yoon, Seoul National University Bundang Hospital:
drug eluting balloon
bare metal stent
drug eluting stent
coronary artery disease

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Angina Pectoris
Angina, Stable
Angina, Unstable
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Chest Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017